Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Obstructive Lung Disease
•
Asthma
What is your preferred rescue inhaler for patients with asthma?
Do you favor albuterol PRN, albuterol/budesonide PRN, or SMART therapy with ICS/formoterol?
Answer from: at Community Practice
The problem with using ICS/formoterol is that the patient will run out of doses before the end of the month if they take it on a BID basis.
Sign In
or
Register
to read more
Answer from: at Academic Institution
SMART with ICS/formoterol. I tend to think all asthma patients should be on SMART therapy (ICS/formoterol). Just don't really see the reason to not treat that way.
Sign In
or
Register
to read more
26869
27010
Related Questions
Have you observed adverse mental health side effects in patients who start montelukast?
Do you plan to use benralizumab to treat acute exacerbations of asthma or COPD associated with eosinophilia?
What is the rationale/evidence to support doing 4 puffs of albuterol vs. 2 puffs for a reversibility study?
Would you stop Dupixent in an asthma patient who has good asthma control and notes improvement in loss of smell, but shows notable eosinophil elevation after 4-5 doses of the medication?
How might the introduction of brensocatib as a treatment option impact the use of other anti- inflammatory or antibiotic therapies currently employed in bronchiectasis management?
How do you choose between dupilumab and mepolizumab for managing COPD in patients with eosinophilia?
Would you consider switching to benralizumab for patients with EGPA experiencing severe pulmonary symptoms despite being on mepolizumab?
Do you utilize cytokine panels to guide treatment of patients with EGPA?
When do you consider switching from another biologic to benralizumab in patients with severe eosinophilic asthma with a history of suboptimal response to previous biologic agents?
Which patient characteristics or scenarios drive you to choose tezepelumab over dupilumab for asthma?